What does a 503A pharmacy need to prepare mazdutide lawfully?

I have been through one internal appeal already and would like to do the next one properly.

This is presented as though it settles something, and I am not convinced it does.

I have two documents that appear to disagree, which is what prompted this.

Which parts of this are informative and which are decoration?

Section 503A is an exemption, not an approval, and it is conditional on four things. A patient-specific prescription; a licensed pharmacist or physician doing the compounding in a licensed facility; bulk substances that either have a USP monograph, appear on the FDA's 503A bulks list, or are components of an approved drug, each with a certificate of analysis from a registered supplier; and the preparation must not be essentially a copy of a commercially available drug. That last condition is the one that moves: it turns on the shortage list, and what was lawful under 503A while a product was in shortage stops being lawful when the shortage is resolved. None of the four requires the finished preparation to be tested, which is the gap that independent assay fills.

Answer first: the two categories differ in whether a prescription for a named patient is required and in which quality standards apply, and that difference decides everything downstream.

Patient-specific compounding requires a prescription for a named individual, is regulated primarily at state level, and is not subject to current good manufacturing practice requirements.

The practical consequences: an outsourcing facility can supply office stock and distribute at volume; a patient-specific compounder cannot do either without stepping outside its category.

Check the registration list. It takes a minute and it is the one verifiable claim here.

The honest answer is that the category tells you about obligations rather than about the quality of any particular preparation.

Registration status is published and searchable. Checking it takes a minute and is the single most useful verification available in this whole area.

A facility that will not say which category it operates under has told you something, and the registration lists will tell you the rest.

The caveat is that this structure is specific to one jurisdiction and does not describe the position elsewhere.

Neither category is an approved product. That is unchanged by registration.

The short version: patient-specific compounding under one framework, office-stock production under the other, with much heavier obligations on the second.

Neither category produces an approved product. Both operate outside the marketing-authorisation framework, and the difference is in the manufacturing standards applied, not in approval status.

On the detail: adverse event reporting obligations attach to the outsourcing category and not to the patient-specific one, which is a real difference in the information that exists about what a facility produces.

The two-tier structure separating patient-specific compounding from outsourcing facilities is established in federal law and the registration lists are published.

The category tells you which standards apply, not how good the preparation is.

Answering this needs the jurisdiction, since this two-tier structure is a feature of one national framework and does not translate directly elsewhere.

Beyond-use dating differs by category and by the preparation environment, and an unusually long date on a compounded sterile preparation is worth asking about.

Adverse event reporting obligations attach to registered outsourcing facilities and are the basis for what public information exists.

A registration category describes obligations, not the quality of any particular preparation.

Inspection findings are public for registered facilities. Read them.

It helps to be literal here: this is a regulatory question with a clean answer, unusually for this family.

Outsourcing facilities may produce without a patient-specific prescription, register federally, are inspected on a risk-based schedule and are subject to current good manufacturing practice.

Current good manufacturing practice applies to the outsourcing category and not to patient-specific compounding, which is the substantive regulatory difference.

This structure is jurisdiction-specific. It does not describe your country unless it does.